Potential of Glycyrrhiza in the prevention of colitis-associated colon cancer

被引:0
|
作者
Liu, Fang [1 ,2 ]
Gu, Zhili [2 ]
Yi, Feiyang [2 ]
Liu, Xue [2 ]
Zou, Wenxuan [2 ]
Xu, Qingxia [1 ]
Yuan, Yun [1 ]
Chen, Nianzhi [3 ]
Tang, Jianyuan [1 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610075, Peoples R China
[2] North Sichuan Med Coll, Nanchong, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 200000, Peoples R China
基金
中国博士后科学基金;
关键词
Glycyrrhiza; Colitis-associated Colon Cancer; Inflammatory Bowel Disease; Precancerous lesions; Dietary supplement; NF-KAPPA-B; COLORECTAL-CANCER; GLYCYRRHETINIC ACID; ULCERATIVE-COLITIS; SAFETY ASSESSMENT; INDUCED TOXICITY; GUT MICROBIOTA; CYCLE ARREST; UPLC-MS/MS; RAT PLASMA;
D O I
10.1016/j.fitote.2025.106398
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ethnopharmacological relevance: Glycyrrhiza, a legume native to the Mediterranean region, has a long history of ethnomedicinal use in China. Due to its antiviral, antibacterial, anti-inflammatory, antioxidant, antitumor, antiulcer, and hepatoprotective properties, Glycyrrhiza is widely utilized in the treatment of gastrointestinal disorders. The aim of the review: The specific mechanisms of the main active constituents of glycyrrhiza in the treatment of inflammatory bowel disease, precancerous lesions and colorectal cancer at all stages of the colitis-associated colon cancer "Inflammation-Dysplasia-Cancer" sequence, as well as its pharmacokinetics, toxicology, formulation improvements, and application studies, are reviewed to provide new insights and perspectives on glycyrrhiza as a dietary supplement to treat and prevent colitis-associated colon cancer. Materials and methods: Information on Glycyrrhiza was retrieved from electronic databases, including PubMed and Web of Science. Results: Glycyrrhiza is a well-established medicinal plant with significant potential for applications in both the food and pharmaceutical industries. Over 400 active constituents have been identified in Glycyrrhiza, including terpenoids, flavonoids, isoflavones, coumarins, and polyphenols. Numerous studies have demonstrated that Glycyrrhiza and its active compounds can inhibit the "Inflammation-Dysplasia-Cancer" progression of colitis associated colon cancer by mitigating inflammatory bowel disease, reducing the number of intestinal precan- cerous lesions, and counteracting colorectal cancer. Furthermore, derivatives and nanocarriers are crucial for the effective treatment of colitis-associated colon cancer using Glycyrrhiza and its active constituents. Conclusion: In conclusion, Glycyrrhiza is a plant with both medicinal and nutritional value, making it a potential food ingredient and dietary supplement for the treatment of colitis-associated colon cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Inhibition of TLR4 Signaling Impedes Tumor Growth in Colitis-Associated Colon Cancer
    Pastille, Eva
    Fassnacht, Tabea
    Adamczyk, Alexandra
    Nhi Ngo Thi Phuong
    Buer, Jan
    Westendorf, Astrid M.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [32] Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer
    Zhang, Maorun
    Li, Xiaoping
    Zhang, Qi
    Yang, Jiahua
    Liu, Gang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] Role of Transforming Growth Factor-β in Inflammatory Bowel Disease and Colitis-associated Colon Cancer
    Feagins, Linda A.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (11) : 1963 - 1968
  • [34] Use of a novel genetic mouse model to investigate the role of folate in colitis-associated colon cancer
    Chapkin, Robert S.
    Kamen, Barton A.
    Callaway, Evelyn S.
    Davidson, Laurie A.
    George, Nysia I.
    Wang, Naisyin
    Lupton, Joanne R.
    Finnell, Richard H.
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2009, 20 (08) : 649 - 655
  • [35] Genomic characterization of colitis-associated colorectal cancer
    Kameyama, Hitoshi
    Nagahashi, Masayuki
    Shimada, Yoshifumi
    Tajima, Yosuke
    Ichikawa, Hiroshi
    Nakano, Masato
    Sakata, Jun
    Kobayashi, Takashi
    Narayanan, Sumana
    Takabe, Kazuaki
    Wakai, Toshifumi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [36] Immunopathogenesis of Colitis-Associated Cancer in an Animal Model
    Zhao, Jun-Lin
    Xiao, Chuan-Xing
    Guleng, Bayasi
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2015, 25 (03): : 245 - 251
  • [37] Fluorescence endoscopic detection of murine colitis-associated colon cancer by topically applied enzymatically rapid-activatable probe
    Mitsunaga, Makoto
    Kosaka, Nobuyuki
    Choyke, Peter L.
    Young, Matthew R.
    Dextras, Christopher R.
    Saud, Shakir M.
    Colburn, Nancy H.
    Sakabe, Masayo
    Nagano, Tetsuo
    Asanuma, Daisuke
    Urano, Yasuteru
    Kobayashi, Hisataka
    GUT, 2013, 62 (08) : 1179 - 1186
  • [38] Status of colitis-associated cancer in ulcerative colitis
    Tetsushi Kinugasa
    Yoshito Akagi
    World Journal of Gastrointestinal Oncology, 2016, (04) : 351 - 357
  • [39] Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer
    Lee, Chan Hyung
    Koh, Seong-Joon
    Radi, Zaher A.
    Habtezion, Aida
    INTESTINAL RESEARCH, 2023, 21 (03) : 295 - 305
  • [40] Alternative Splicing at the Crossroad of Inflammatory Bowel Diseases and Colitis-Associated Colon Cancer
    Matos, Paulo
    Jordan, Peter
    CANCERS, 2025, 17 (02)